MOMichael Odo

Michael Odo

*This is an algorithmically generated author record based on publicly available information.

Michael Odo has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Liberia adherence and loss-to-follow-up in HIV and AIDS care and treatment: A retrospective cohort of adolescents and adults from 2016–2019

    by Keith L. Gray, Murphy Kiazolu, Janjay Jones, Anna Konstantinova, Jethro S. W. Zawolo, Wahdae-Mai Harmon Gray, Naomi F. Walker, Julia T. Garbo, Samretta Caldwell, Michael Odo, et al.

    Background: Antiretroviral therapy (ART) is a lifesaving intervention for people living with HIV infection, reducing morbidity and mortality; it is likewise essential to reducing transmission. The “Treat all” strategy recommended by the World Health Organization has dramatically increased ART eligibility and improved access. However, retaining patients on ART has been a major challenge for many national programs in low- and middle-income settings, despite actionable local policies and ambitious targets. To estimate retention of patients along the HIV care cascade in Liberia, and identify factors associated with loss-to-follow-up (LTFU), death, and suboptimal treatment adherence, we conducted a nationwide retrospective cohort study utilizing facility and patient-level records. Patients aged ≥15 years, from 28 facilities who were first registered in HIV care from January 2016 –December 2017 were included. We used Cox proportional hazard models to explore associations between demographic and clinical factors and the outcomes of LTFU and death, and a multinomial logistic regression model to investigate factors associated with suboptimal treatment adherence. Among the 4185 records assessed, 27.4% (n = 1145) were males and the median age of the cohort was 37 (IQR: 30–45) years. At 24 months of follow-up, 41.8% (n = 1751) of patients were LTFU, 6.6% (n = 278) died, 0.5% (n = 21) stopped treatment, 3% (n = 127) transferred to another facility and 47.9% (n = 2008) were retained in care and treatment. The incidence of LTFU was 46.0 (95% CI: 40.8–51.6) per 100 person-years. Relative to patients at WHO clinical stage I at first treatment visit, patients at WHO clinical stage III [adjusted hazard ratio (aHR) 1.59, 95%CI: 1.21–2.09; p <0.001] or IV (aHR 2.41, 95%CI: 1.51–3.84; p <0.001) had increased risk of LTFU; whereas at registration, age category 35–44 (aHR 0.65, 95%CI: 0.44–0.98, p = 0.038) and 45 years and older (aHR 0.60, 95%CI: 0.39–0.93, p = 0.021) had a decreased risk. For death, patients assessed with WHO clinical stage II (aHR 2.35, 95%CI: 1.53–3.61, p<0.001), III (aHR 2.55, 95%CI: 1.75–3.71, p<0.001), and IV (aHR 4.21, 95%CI: 2.57–6.89, p<0.001) had an increased risk, while non-pregnant females (aHR 0.68, 95%CI: 0.51–0.92, p = 0.011) and pregnant females (aHR 0.42, 95%CI: 0.20–0.90, p = 0.026) had a decreased risk when compared to males. Suboptimal adherence was strongly associated with the experience of drug side effects–average adherence [adjusted odds ratio (aOR) 1.45, 95% CI: 1.06–1.99, p = 0.02) and poor adherence (aOR 1.75, 95%CI: 1.11–2.76, p = 0.016), and attending rural facility decreased the odds of average adherence (aOR 0.01, 95%CI: 0.01–0.03, p<0.001) and poor adherence (aOR 0.001, 95%CI: 0.0004–0.003, p<0.001). Loss-to-follow-up and poor adherence remain major challenges to achieving viral suppression targets in Liberia. Over two-fifths of patients engaged with the national HIV program are being lost to follow-up within 2 years of beginning care and treatment. WHO clinical stage III and IV were associated with LTFU while WHO clinical stage II, III and IV were associated with death. Suboptimal adherence was further associated with experience of drug side effects. Active support and close monitoring of patients who have signs of clinical progression and/or drug side effects could improve patient outcomes.


  • Open Access

    Screening for HIV Among Patients at Tuberculosis Clinics — Results from Population-Based HIV Impact Assessment Surveys, Malawi, Zambia, and Zimbabwe, 2015–2016

    by Nikhil Kothegal, Alice Wang, Sasi Jonnalagadda, Adam MacNeil, Elizabeth Radin, Kristin Brown, Owen Mugurungi, Regis Choto, Shirish Balachandra, John H. Rogers, et al.

    This report describes screening for HIV in patients at tuberculosis clinics in Africa.


  • Open Access

    TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice

    by Michael Odo, Kingsley Chinedum Ochei, Emmanuel Ifeanyi Obeagu, Afirima Barinaadaa, Ugobo Emmanuel Eteng, Mabel Ikpeme, Jonah Offor Bassey, Andrew Ogar Paul

    TB and HIV remain a dangerous duo of significant public health concern across the globe. Both diseases require significant community and health system activities to be successfully managed. TB infection control is an important disease prevention strategy among the general population and among people living with HIV, in cost and management. We undertook to assess the situation of TB infection control at three levels of health care in Cross River State of Nigeria. A qualitative method was used to assess TB infection control (TBIC) knowledge, attitudes, and practices of the health care workers at each of the purposefully selected facilities using a semi-structured questionnaire - University of Calabar Teaching hospital, Calabar; Infectious disease Hospital, Calabar and primary Health Centre, Calabar Municipal, between 15th to 31st November, 2019 in the first phase, and an extension to February, 2020 due to delayed ethical clearance from the University of Calabar Teaching hospital. Data was collected and entered on an excel template and cleaned by trained data entry clerks. Charts and color diagrams were developed to compare specific descriptive data. There is wide variation between the written policies of TB infection control and the practices among health workers. Even though there are strong administrative protocols to support TB infection control in the higher levels of care, it is better practiced in the lower level PHC where the protocols were not spelt out.